Granem

Granem is an oral medication that contains the active ingredient granisetron hydrochloride. It is supplied as a prescription‑only product in the European market and belongs to the 5‑HT3 receptor antagonist class. Granem works by selectively blocking peripheral and central 5‑HT3 receptors, which helps to reduce nausea and vomiting associated with chemotherapy or surgery. The formulation is intended for adult patients under medical supervision and appropriate.

Granem is indicated for the prevention of nausea and vomiting in specific clinical situations.

- Prevention of chemotherapy‑induced nausea and vomiting (CINV) in adult patients. - Prevention of postoperative nausea and vomiting (PONV) following surgical procedures. - Use as part of a multimodal antiemetic regimen when other agents are insufficient. - Administration before the start of emetogenic chemotherapy or surgery to maximize efficacy. - May be considered for patients with a high risk of acute nausea based on treatment protocols. - Use in combination with dexamethasone for enhanced control of delayed nausea.

The safety profile of Granem includes both common and less frequent adverse reactions that have been reported in clinical use.

Common: - Headache – mild to moderate intensity, often transient. - Constipation – reduced bowel movements, may respond to dietary fiber. - Diarrhoea – loose stools, usually self‑limiting. - Fatigue – feeling of tiredness without exertion. - Dizziness – light‑headed sensation, especially when standing quickly.

Serious: - Severe allergic reaction (anaphylaxis) – swelling, rash, difficulty breathing. - Cardiac arrhythmia (QT prolongation) – irregular heartbeat, requires ECG monitoring. - Serotonin syndrome – agitation, hyperthermia, muscle rigidity when used with serotonergic agents.

Before prescribing Granem, clinicians should evaluate several precautionary factors to ensure safe use in individual patients.

- Assess cardiac history, especially for prolonged QT interval or electrolyte disturbances. - Use caution in patients with hepatic impairment; dose adjustment may be required. - Evaluate renal function, as severe renal failure can affect drug clearance. - Avoid use in patients with known hypersensitivity to granisetron or other 5‑HT3 antagonists. - Consider pregnancy and breastfeeding status; safety data are limited. - Monitor for signs of serotonin syndrome when combined with serotonergic medications. - Review concomitant medications that may prolong QT interval.

Granem may interact with other medicines, and certain combinations should be avoided or used with heightened monitoring.

Avoid: - Other 5‑HT3 antagonists – additive antiemetic effect without added benefit. - Drugs that markedly prolong the QT interval (e.g., certain antiarrhythmics, antipsychotics). - Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin) that could increase granisetron levels.

Use with caution: - Serotonergic agents such as SSRIs, SNRIs, tramadol, or linezolid – risk of serotonin syndrome. - Antifungal azoles and macrolide antibiotics – may modestly raise plasma concentrations. - Medications that affect electrolyte balance (e.g., diuretics) – may increase QT prolongation risk.